Compare Stocks → A lot of people are making this costly mistake (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENTXNASDAQ:NTGNNASDAQ:ONVONASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.67+8.4%$1.17$0.52▼$1.87$48.10M1.68203,592 shs124,619 shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/AONVOOrganovo$1.03+2.0%$1.02$0.89▼$2.31$10.34M0.9145,579 shs43,870 shsOTLKOutlook Therapeutics$11.94+27.4%$8.21$4.00▼$40.60$155.34MN/A1.43 million shs1.56 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+8.44%-2.91%+62.93%+178.33%+23.70%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%ONVOOrganovo+1.98%0.00%+5.10%-7.21%-54.42%OTLKOutlook Therapeutics+27.43%+69.60%+34.79%+51.52%-43.14%$25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio2.0264 of 5 stars3.53.00.00.02.81.70.0NTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONVOOrganovo0.9043 of 5 stars0.05.00.00.02.50.01.3OTLKOutlook Therapeutics3.528 of 5 stars4.44.00.00.03.80.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio3.00Buy$10.00498.80% UpsideNTGNNeon TherapeuticsN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43288.82% UpsideCurrent Analyst RatingsLatest OTLK, ENTX, NTGN, and ONVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.001/25/2024OTLKOutlook TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$31.401/25/2024OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$40.0012/29/2023OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $40.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$130K369.97N/AN/A$0.36 per share4.64NTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/AONVOOrganovo$370K27.95N/AN/A$1.76 per share0.59OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$8.89M-$0.31N/A∞N/AN/A-101.78%-83.90%5/3/2024 (Estimated)NTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/AONVOOrganovo-$17.26M-$2.17N/AN/AN/A-4,061.12%-182.88%-138.52%7/11/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)Latest OTLK, ENTX, NTGN, and ONVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/A2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A10.3210.32NTGNNeon Therapeutics0.431.583.00ONVOOrganovoN/A3.673.67OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%NTGNNeon Therapeutics54.71%ONVOOrganovo8.23%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio8.90%NTGNNeon Therapeutics38.93%ONVOOrganovo4.00%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio1928.80 million26.24 millionOptionableNTGNNeon Therapeutics10228.97 millionN/ANot OptionableONVOOrganovo1510.04 million9.64 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionNot OptionableOTLK, ENTX, NTGN, and ONVO HeadlinesSourceHeadlineOutlook from the C-Suite: Freeman and GES Leaders Share Their Biggest Business Concernstsnn.com - March 29 at 10:26 AMHow to fight the new Windows Outlook app and keep Mail…for nowpcworld.com - March 28 at 2:25 PMOutlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to "Buy"americanbankingnews.com - March 28 at 4:20 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Down 93.3% in Marchmarketbeat.com - March 27 at 10:15 PMBuy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Targetmarkets.businessinsider.com - March 27 at 3:13 PMOutlook Therapeutics shares rise after 'buy' rating from BTIGmsn.com - March 27 at 3:13 PMOutlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to Buymarketbeat.com - March 27 at 8:30 AMQ2 2024 Earnings Estimate for Outlook Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:OTLK)americanbankingnews.com - March 27 at 6:02 AMOutlook Therapeutics (NASDAQ:OTLK) Given New $30.00 Price Target at HC Wainwrightamericanbankingnews.com - March 26 at 3:56 AMOutlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Successmarkets.businessinsider.com - March 25 at 7:36 PMHC Wainwright Raises Outlook Therapeutics (NASDAQ:OTLK) Price Target to $30.00marketbeat.com - March 25 at 8:48 AMBuy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market Potentialmarkets.businessinsider.com - March 25 at 5:33 AMOutlook Therapeutics Surges On Positive CHMP Opinion For ONS-5010nasdaq.com - March 24 at 7:33 PMWhy Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?msn.com - March 22 at 3:36 PMOutlook Therapeutics Shares Rise Premarket on CHMP Backing of Wet AMD Drugmarketwatch.com - March 22 at 10:35 AMCanopy Growth, Capricor Therapeutics, GT Biopharma among healthcare moversmsn.com - March 22 at 10:35 AMOutlook Therapeutics Receives Positive CHMP Opinion For ONS-5010 To Treat Wet AMDmarkets.businessinsider.com - March 22 at 10:35 AMOutlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDglobenewswire.com - March 22 at 7:35 AMQ2 2024 EPS Estimates for Outlook Therapeutics, Inc. (NASDAQ:OTLK) Raised by Analystamericanbankingnews.com - March 22 at 2:18 AMAll You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buyzacks.com - March 21 at 1:01 PMResearch Analysts Issue Forecasts for Outlook Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:OTLK)marketbeat.com - March 21 at 8:04 AMBuy Rating Affirmed for Outlook Therapeutics Amidst Strong Financial Positioning and Advancing Clinical Trialsmarkets.businessinsider.com - March 19 at 5:22 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Brokeragesamericanbankingnews.com - March 19 at 4:34 AMOutlook Therapeutics® Announces Closing of Private Placement of up to $159 Millionglobenewswire.com - March 18 at 5:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEntera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Neon TherapeuticsNASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.